免疫检查点在结直肠癌治疗中的研究现状  

Research status of immune checkpoint in the treatment of colorectal cancer

作　　者：黄锐 丁杰 曾家兴[2] 樊斐 Huang Rui;Ding Jie;Zeng Jiaxing;Fan Fei(Clinical Medical College of Guizhou Medical University,Guiyang 550004,China;Department of Gastrointestional Surgery,Guizhou Provincial People′s Hospital,Guiyang 550002,China)

机构地区：[1]贵州医科大学临床医学院,贵阳550004 [2]贵州省人民医院胃肠外科,贵阳550002

出　　处：《中华实验外科杂志》2021年第12期2562-2565,共4页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(81360366、81302169);贵州省科技计划项目(黔科合基础[2019]1198号,黔科合基础[2020]1Z064)。

摘　　要：随着肿瘤免疫疗法的研究,免疫治疗已成为继手术、化学疗法、放射疗法和靶向治疗之后又一种治疗结直肠癌的重要手段。其中免疫检查点通过对适应性免疫反应进行调节,从而促进癌细胞发生免疫逃逸,在癌症的发生发展中发挥着重要作用。近年来,以程序性细胞死亡蛋白1(PD-1)/程序性细胞死亡配体1(PD-L1)及细胞毒性T淋巴细胞抗原4(CTLA-4)抗体为代表的免疫检查点抑制剂在结直肠癌尤其是微卫星高度不稳定性(MSI-H)/错配修复缺陷(dMMR)结直肠癌治疗中发挥重要作用。本文针对PD-1/PD-L1及CTLA-4抗体在结直肠癌治疗领域的研究现状展开综述。With the development of tumor immunotherapy,immunotherapy has become an important method for the treatment of advanced colorectal cancer after surgery,chemotherapy,radiotherapy and targeted therapy.Immune checkpoint plays an important role in the occurrence and development of cancer by regulating adaptive immune response and promoting immune escape of cancer cells.In recent years,immune checkpoint inhibitors such as programmed cell death protein-1(PD-1)/programmed cell death-ligand 1(PD-L1)and(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)antibodies play an important role in the treatment of colorectal cancer,especially microsatellite instability-high(MSI-H)/mis-match repair deficiency(dMMR).In this paper,the research status of PD-1/PD-L1 and CTLA-4 antibodies in the treatment of colorectal cancer is reviewed.

关 键 词：结直肠癌 免疫检查点 免疫治疗 程序性细胞死亡蛋白1 程序性细胞死亡配体1 细胞毒性T淋巴细胞抗原4 

分 类 号：R735.34[医药卫生—肿瘤]